IP Library Granted Patent US 9,596,870
Granted Patent B2
US 9,596,870 · App. 14/310,359 · Granted Mar 21, 2017

Compositions and methods for enhancing exercise performance

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,596,870
App. No.
14/310,359
Granted
Mar 21, 2017
Kind
B2
Abstract

Compositions and methods are provided for improving canine exercise performance. The compositions are pre-exercise supplements that generally comprise (a) about 35% to about 60% protein or amino acids, comprising one or more structural proteins, one or more bioavailable proteins and one or more branched chain amino acids; (b) about 20% to about 38% fat, comprising at least one source of medium chain triglycerides; and (c) about 5% to about 25% carbohydrate. The methods involve administering the supplement to the animal within about 30-60 minutes before the beginning of the exercise session. The supplements can be administered in conjunction with one or more other exercise performance-enhancing or recovery agents.

Claims (15)

1. A method for improving exercise performance in a canine, comprising:

a. identifying a canine that will be performing exercise; and

b. administering to the canine a pre-exercise supplement in an effective amount, the pre-exercise supplement comprising (i) about 35% to about 60% protein or amino acids, comprising one or more structural proteins, one or more bioavailable proteins and one or more branched chain amino acids; (ii) about 20% to about 38% fat, comprising at least one source of medium chain triglycerides; and (iii) about 5% to about 25% carbohydrate, wherein the supplement is formulated to provide the canine with between about 1.2 g/kg BW and about 2.0 g/kg BW total nutrition,

wherein the supplement is administered to the canine between about zero and about 60 minutes prior to exercise.

2. The method of claim 1 , wherein the supplement is administered to the canine between about zero and about 30 minutes prior to exercise.

3. The method of claim 1 , wherein the structural protein in the supplement includes animal muscle.

4. The method of claim 3 , wherein the muscle is heart muscle.

5. The method of claim 1 , wherein the bioavailable protein in the supplement is selected from whey, partially hydrolyzed soy and hydrolyzed amino acids, or any combination thereof.

6. The method of claim 1 , wherein the branched chain amino acids in the supplement include L-leucine.

7. The method of claim 1 , wherein the source of medium chain triglycerides in the supplement is coconut oil.

8. The method of claim 1 , wherein the carbohydrate in the supplement comprises complex carbohydrates.

9. The method of claim 1 , wherein administration of the supplement does not cause a substantial increase in blood insulin.

10. The method of claim 1 , wherein, relative to a control animal not receiving the supplement, the blood level of branched chain amino acids is increased 30 to 60 minutes after the animal ingests the supplement.

11. The method of claim 1 , wherein the supplement comprises leucine and, relative to a control animal not receiving the supplement, the blood level of the leucine is increased 30 to 60 minutes after the animal ingests the supplement.

12. The method of claim 1 , wherein the effective amount provides at least one of the following: (1) increased BCAA in the blood within 30 minutes following administration, (2) increased leucine in the blood within 30 minutes following administration; (3) increased availability of free fatty acids or glycerol for exercising muscles as measured by an increase of the free fatty acids or the glycerol in blood circulating levels; (4) insulin secretion of no more than 5% increase following administration; (5) reduction of activity-induced protein catabolism; (6) increased protein biosynthesis (7) stable or increased blood oxygenation, (8) reduced production of at least one stress hormone; (9) reduced production of protein oxidation products, (10) increased or reduced-depletion of endogenous pH buffering agents including beta-alanine or carnosine; and (11) reduced fatigue or reduced soreness.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2017
From: ZANGHI, BRIAN M; REYNOLDS, ARLEIGH J; MIDDLETON, RONDO P
To: NESTEC SA
Reel/Frame 041861/0877 →